These data indicated that the STING activation of the SH-NPs would potently stimulate an immunogenic tumor immune microenvironment with relieved immunosuppression, which is highly important for improving the cancer immunotherapeutic efficacy. The gene discussed is STING1; the disease is neoplasm.